Skip to main
  1. Stocks
  2. LB Pharmaceuticals Inc
  3. Forecast
LBRX

LBRX Stock Forecast & Price Target

LBRX Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 67%
Buy 22%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

LB Pharmaceuticals is supported by a de-risked lead asset in LB-102, which has already shown statistically significant Phase 2 schizophrenia efficacy across all three doses, including placebo-adjusted PANSS improvements of 5.0, 4.7, and 6.8 points, alongside dose-dependent cognitive gains and a favorable tolerability profile with low EPS and minimal sedation. The fundamental bull case also rests on a differentiated, re-engineered amisulpride platform that enables once-daily dosing at far lower exposure than the ex-U.S. drug, while preserving a bimodal mechanism that can extend into bipolar depression and adjunctive MDD. With pro forma cash of about $478M funding operations beyond Q2 2029 and catalysts spanning NOVA-2 in 1H 2027, ILLUMINATE-1 in Q1 2028, and adjunctive MDD in 1H 2029, the company has both scientific and financial runway.

Bears say

LB Pharmaceuticals is exposed to substantial clinical and regulatory risk because its outlook depends on LB-102 succeeding in late-stage development while the company itself flags NOVA-2 primary miss risk, unexpected safety and tolerability signals, and possible delays in schizophrenia and bipolar depression programs. The bearish case is reinforced by competitive pressure and weakening category evidence, including emraclidine’s failed registrational Phase 2 dose, Cobenfy’s largest Phase 3 missing its prespecified PANSS-negative endpoint at week 5, and the broader observation that efficacy can diminish in larger Phase 3 studies. Finances also remain a concern, as the company faces financing risk until cash flow positive, while step-therapy positioning, other R&D setbacks, and regulatory uncertainty could limit commercial optionality.

LBRX has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 22% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LB Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

LBRX Analyst Forecast & Price Prediction

Get the latest LBRX stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in LBRX

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LB Pharmaceuticals Inc (LBRX) Forecast

Analysts have given LBRX a Strong Buy based on their latest research and market trends.

According to 9 analysts, LBRX has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $53.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $53.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LB Pharmaceuticals Inc (LBRX)


LBRX Analyst Forecast & Price Prediction

Get the latest LBRX stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in LBRX

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover LBRX stock data and trends